The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial
Open accessPublished version of a preprint
Abstract
Background: Mesenchymal stem cell (MSC) infusion was reported to improve liver function in patients with decompensated liver cirrhosis (DLC); however, whether the medication can improve outcome of these patients is poorly understood. Methods: This prospective, open-labeled, randomized controlled study enrolled 219 patients with HBV-related DLC who were divided into control group ( n = 111) and umbilical cord-derived MSC (UC-MSC)-treated group ( n = 108), then all of them received a follow-up check from October 2010 to October 2017. The treated patients received three times of UC-MSC infusions at 4-week intervals plus conventional treatment that was only used for control group. The overall survival rate and HCC-free survival rate were calculated as primary endpoints and the liver function and adverse events associated with the medication were also evaluated. Results: During the follow-up check period from 13 to 75th months, there was a significantly higher overall survival rate in the treated group than the control group, while the difference of the hepatocellular carcinoma event-free survival rate between the treated and control groups was not observed during the 75-month follow-up. UC-MSC treatment markedly improved liver function, as indicated by the levels of serum albumin, prothrombin activity, cholinesterase, and total bilirubin during 48 weeks of follow-up. No significant side effects or treatment-related complications were observed in the UC-MSC group. Conclusions: Therapy of UC-MSC is not only well tolerated, but also significantly improves long-term survival rate, as well as the liver function in patients with HBV-related DLC. UC-MSC medication, therefore, might present a novel therapeutic approach for the disease. Graphic abstract:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common side effect observed was fever, which could be subsided by regular antipyretics [287, 292, 300].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [287]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared to the control group, the treated group had a significantly higher overall survival rate from 13 to 75 months and markedly improved liver functions, as evidenced by serum ALB, PTA, CHE, and TBIL levels during 48 weeks.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [287]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal stem cells in health and disease
Uccelli, A., Moretta, L., & Pistoia, V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2395 · Cited by 3,746
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M. E., Remberger, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60690-x · Cited by 2,695
Røsland, G. V., Svendsen, A., Torsvik, A., Sobala, E., McCormack, E., Immervoll, H., Mysliwietz, J., Tonn, J.-C., Goldbrunner, R., Lønning, P. E., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4630 · Cited by 644
Kharaziha, P., Hellström, P. M., Noorinayer, B., Farzaneh, F., Aghajani, K., Jafari, F., Telkabadi, M., Atashi, A., Honardoost, M., Zali, M. R., et al. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832a1f6c · Cited by 492 · cited 1×
“In the clinical setting, several studies have shown that infusions of autologous BM-MSC can significantly improve liver function in patients with liver cirrhosis [6, 7].”
BackgroundTerai, S., Ishikawa, T., Omori, K., Aoyama, K., Marumoto, Y., Urata, Y., Yokoyama, Y., Uchida, K., Yamasaki, T., Fujii, Y., et al. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0542 · Cited by 491
Ramasamy, R., Lam, E. W.-F., Soeiro, I., Tisato, V, Bonnet, D., & Dazzi, F. (2007) · Leukemia · doi:10.1038/sj.leu.2404489 · Cited by 404
Shi, M., Zhang, Z., Xu, R., Lin, H., Fu, J., Zou, Z., Zhang, A., Shi, J., Chen, L., Lv, S., et al. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0034 · Cited by 374
Self-citationZhang, Z., Lin, H., Shi, M., Xu, R., Fu, J., Lv, J., Chen, L., Lv, S., Li, Y., Yu, S., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07024.x · Cited by 372 · cited 2×
“Our previous studies showed that UC-MSC infusion significantly improved liver function in patients with decompensated liver cirrhosis [12] and primary biliary cirrhosis [13] and increased the survival rates of patients with acute-on-chronic liver failure (ACLF) [14].”
BackgroundSelf-citationPeng, L., Xie, D.-Y., Lin, B.-L., Liu, J., Zhu, H.-P., Xie, C., Zheng, Y.-B., & Gao, Z.-L. (2011) · Hepatology · doi:10.1002/hep.24434 · Cited by 365
Cited by
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
Zhang, Z., Shang, J., Yang, Q., Dai, Z., Liang, Y., Lai, C., Feng, T., Zhong, D., Zou, H., Ji, G., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01788-4 · Cited by 131
Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy
Wu, R., Fan, X., Wang, Y., Shen, M., Zheng, Y., Zhao, S., & Yang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.833878 · Cited by 142
Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment
Yang, X., Li, Q., Liu, W., Zong, C., Wei, L., Shi, Y., & Han, Z. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00983-5 · Cited by 120
Metadata
- Authors
- Shi, M., Li, Y.-Y., Xu, R.-N., Meng, F.-P., Yu, S.-J., Fu, J.-L., Hu, J.-H., Li, J.-X., Wang, L.-F., Jin, L., & Wang, F.-S.
- Affiliations
- Chinese PLA General Hospital (CN)
- Corresponding author
- Shi, Ming
- Wang, Fu-Sheng
- Venue
- Hepatology International
- Published
- 2021-11-29
- Volume
- 15
- Issue
- 6
- Pages
- 1431-1441
- ISSN
- 1936-0533 (ISSN-L)
- 1936-0541
- PMC
- PMC8651584
- OpenAlex
- W3166597897
- Cited by
- 151
- References
- 32
- Citations by year
- 2026: 25 · 2025: 39 · 2024: 35 · 2023: 35 · 2022: 17
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Hepatology International (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- the National Key R&D Program of China (2017YFA0105703)
- National Natural Science Foundation of China (82070617)
- Innovative Research Group Project of the National Natural Science Foundation of China (81721002)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- mesenchymal stem cells, umbilical cord-derived stem cells, decompensated cirrhosis, HBV-related liver cirrhosis, stem cell therapy, overall survival, liver function, long-term follow-up, treatment safety
- MeSH terms
- Follow-Up Studies, Humans, Liver Cirrhosis, Prospective Studies, Treatment Outcome, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial. https://app.cochat.ai/papers/10.1007/s12072-021-10199-2
- The paper
- Shi, M., Li, Y.-Y., Xu, R.-N., Meng, F.-P., Yu, S.-J., Fu, J.-L., Hu, J.-H., Li, J.-X., Wang, L.-F., Jin, L., & Wang, F.-S. (2021). Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial. Hepatology International. https://doi.org/10.1007/s12072-021-10199-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.